Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside ...

Moderna shares advanced after the biotechnology company reported higher-than-expected sales of its Covid-19 vaccine and backed its full-year sales forecast.

Even though RGTI stock has already seen an impressive 1,300% increase over the past twelve months, the question persists: ...

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...

The offering, the first IPO this year, attracted more than 32 billion dirhams ($3.5 bln) in demand for 500 million dirhams in shares. GSK seeks FDA nod for expanded use of RSV vaccine in adults ...

Moderna stock has faced heavy pressure from negative headlines, regulatory setbacks and political uncertainty. See why I ...

This stock used to be a highflyer but has struggled in recent years as demand waned for its flagship product. Though Moderna ...

The S&P 500 ticked 0.1% on Monday, July 14, 2025, as trade policy remained in the spotlight to kick off a week that also ...

Moderna (NasdaqGS:MRNA) recently experienced significant index changes, with the company being added to the Russell Midcap and Midcap Value indexes, while being dropped from several others. Over the ...

EST on Bloomberg Television NEW YORK CITY, NY / ACCESS Newswire / July 12, 2025 / New to The Street, the leading ...

The latest trading day saw Moderna (MRNA) settling at $33.64, representing a -1.87% change from its previous close.